Advertisement


Eric Jonasch, MD, on Kidney Cancer: Current and Novel Treatment Options

2015 NCCN Annual Conference

Advertisement

Eric Jonasch, MD, of The University of Texas, MD Anderson Cancer Center, discusses the progress being made in kidney cancer treatment and the clinical trials that focused on sunitinib, sorafenib, and everolimus, among others.



Related Videos

Breast Cancer

Ingrid A. Mayer, MD, on New Therapies for Hormone-Sensitive Advanced Breast Cancer

Ingrid A. Mayer, MD, of the Vanderbilt-Ingram Cancer Center, discusses the evolution of endocrine therapy for metastatic breast cancer.

Gastroesophageal Cancer

Hans Gerdes, MD, on Endoscopic Therapies for Early-Stage Esophageal Cancers

Hans Gerdes, MD, of Memorial Sloan Kettering Cancer Center, discusses a new approach to the management of early-stage esophageal cancers with endoscopic resections.

Peter G. Shields, MD, on New NCCN Guidelines: Smoking Cessation for Patients With Cancer

Peter G. Shields, MD, of The Ohio State University Comprehensive Cancer Center and the James Cancer Hospital and Solove Research Institute, discusses the new NCCN Guidelines for helping patients with cancer to stop smoking. Counseling is a critical part of these new recommendations.

Samuel M. Silver, MD, PhD, and Al B. Benson III, MD, FACP, FASCO, on 20 Years of Improving Cancer Care Together: A Clinical Perspective

Samuel M. Silver, MD, PhD, of the University of Michigan Comprehensive Cancer Center, and Al B. Benson III, MD, FACP, FASCO, of Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discuss the evolution of NCCN Guidelines, which are available free online,  and the components that make them effective: a multidisciplinary approach, the participation of patient advocates, consistency, and affordability of the evidence.

Robert W. Carlson, MD, and John A. Gentile, Jr, on Milestones of NCCN

Robert W. Carlson, MD, Chief Executive Officer, National Comprehensive Cancer Network, and John A. Gentile, Jr, Chairman, Harborside Press, LLC, discuss the early days of NCCN, controversies that surrounded the first meeting, oncologists’ embrace of the guidelines, and how the organization has evolved over the past 20 years.

Advertisement

Advertisement




Advertisement